Photo - PredxBio
play_arrow
View
62666

PredxBio

USA, Pennsylvania
Market: Artificial Intelligence, Biotech
Stage of the project: Operating business

Date of last change: 07.10.2024
Go to the owner's profile
3
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Idea

PredxBio is powering next-generation cancer therapeutics with AI-driven spatial biomarkers, which delves into the mechanism of action of drugs and predicts patient outcomes with over 95% accuracy.

Current Status

5 active paying pharma clients, growing revenue ~$1M. 10+ patents granted, 20+ peer-reviewed journal publications. Strategic partnerships for revenue growth with CROs/channel partners and medical centers. Oversubscribed by $1M and closed conv. note round at $2.8M and Series A1 at $2.1M. Currently raising $2M of Series A-2, participation preferred stock, $1.2M is available.

Market

Problem or Opportunity

There are significant challenges in managing cancer patients as available therapies only work for ~20% of the time. Moreover, 90% of the drugs fail to get to the market after 8+ years of development. There is an urgent unmet need for accessible treatment options for cancer patients.

Solution (product or service)

Biology in the tumor holds the key to response to therapy. We analyze pre-treatment tumor biopsies to predict response and resistance to therapy. We are unraveling the heterogenous dynamics and hidden complexities of the tumor microenvironment by harnessing spatial multi-omics data (e.g., proteomics, transcriptomics, histology) and predict patient outcomes with over 90% accuracy. The insights we provide to our clients are already helping them design their clinical trials/pipelines better.

Competitors

Advantages or differentiators

Finance

Invested in previous rounds, $

Business model

We have a recurring revenue model that includes services, SaaS, and Microdomain Atlas Search model. We are currently generating revenue from biopharma companies via opportunistic service projects in Discovery, Translation and Clinical Trials. For all customers, we have master service agreements (MSA) which allows us to realize the recurring revenue with follow-on projects on multiple ongoing clinical trials.

Money will be spent on

Offer for investor

Team or Management

Mentors & Advisors

Lead investor

Risks

Incubation/Acceleration programs accomplishment

Innovation Works, Alpha Lab Health

Won the competition and other awards

Invention/Patent

Product Video

5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility136
star0
Add to favorites
Delete from favorites
share
close
thumb_up0
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Product Video
Presentation